Robert R Ruffolo Net Worth

The estimated Net Worth of Robert R Ruffolo is at least $152 Thousand dollars as of 1 July 2021. Robert Ruffolo owns over 6,750 units of Sigilon Therapeutics stock worth over $151,673 and over the last 7 years Robert sold SGTX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Robert Ruffolo SGTX stock SEC Form 4 insiders trading

Robert has made over 1 trades of the Sigilon Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Robert exercised 6,750 units of SGTX stock worth $3,848 on 1 July 2021.

The largest trade Robert's ever made was exercising 6,750 units of Sigilon Therapeutics stock on 1 July 2021 worth over $3,848. On average, Robert trades about 563 units every 0 days since 2017. As of 1 July 2021 Robert still owns at least 6,750 units of Sigilon Therapeutics stock.

You can see the complete history of Robert Ruffolo stock trades at the bottom of the page.

What's Robert Ruffolo's mailing address?

Robert's mailing address filed with the SEC is C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET STE 600, CAMBRIDGE, MA, 02142.

Insiders trading at Sigilon Therapeutics

Over the last 4 years, insiders at Sigilon Therapeutics have traded over $2,000,000 worth of Sigilon Therapeutics stock and bought 2,018,493 units worth $31,039,916 . The most active insiders traders include Lilly & Co Eli, Lilly & Co Shenandoah Acqui..., and John Cox. On average, Sigilon Therapeutics executives and independent directors trade stock every 139 days with the average trade being worth of $7,174,671. The most recent stock trade was executed by Lilly & Co Shenandoah Acqui... on 11 August 2023, trading 1,718,493 units of SGTX stock currently worth $25,639,916.

What does Sigilon Therapeutics do?

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Complete history of Robert Ruffolo stock trades at Diffusion Pharmaceuticals Inc, Aridis Pharmaceuticals Inc, and Sigilon Therapeutics

Sigilon Therapeutics executives and stock owners

Sigilon Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA,
  Pres, CEO & Director
• Dr. May Orfali M.B.A., M.D.,
  Exec. VP & Chief Medical Officer
• Philip Ashton-Rickardt Ph.D.,
  Chief Scientific Officer
• Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD,
  Co-Founder & Member of Scientific Advisory Board
• Dr. Daniel G. Anderson Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Dr. José Oberholzer M.D.,
  Co-Founder
• Matthew Kowalsky J.D.,
  Chief Legal Officer
• Robert Windsor Jr., J.D.,
  VP & Head of Investor Relations
• Josias Fantato De Pontes M.B.A.,
  Acting CFO, Sr. VP, Principal Accounting Officer & Treasurer
• Dr. Arturo Vegas Ph.D.,
  Co-Founder
• Dr. José Oberholzer M.D.,
  Co-Founder
• Dr. Omid Veiseh Ph.D.,
  Co-Founder
• Coelho Rogerio Vivaldi,
  PRESIDENT AND CEO
• Glenn Reicin,
  CHIEF FINANCIAL OFFICER
• Deya Corzo,
  CHIEF MEDICAL OFFICER
• Devyn Smith,
  CHIEF OPERATING OFFICER
• Lilly & Co Shenandoah Acqui...,
  
• Douglas G. Cole,
  
• Kavita Patel,
  
• Stephen N. Oesterle,
  
• Eric D. Shaff,
  
• Ventures Fund V General Par...,
  
• John Cox,
  
• Lilly & Co Eli,
  10% owner
• Robert R Ruffolo,
  
• Brooke Story,
  
• Philip Ashton Rickardt,
  CHIEF SCIENTIFIC OFFICER
• Daniel Griffith Anderson,
  
• Qing Sarah Yuan,
  CTOO
• May Orfali,
  CHIEF MEDICAL OFFICER
• Matthew Paul Kowalsky,
  CHIEF OF STAFF AND CLO
• Josias Pontes,
  CHIEF FINANCIAL OFFICER